Discover
ELEV
Elevation Oncology, Inc.
0.36
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | ||
| 1y |
0.36
day range
0.36
0.44
52 week range
5.83
| Open | 0.37 | Prev Close | 0.36 | Low | 0.36 | High | 0.36 | Mkt Cap | 33.90M |
| Vol | 4.38M | Avg Vol | 773.88K | EPS | -0.80 | P/E | N/A | Forward P/E | -0.63 |
| Beta | 1.25 | Short Ratio | 9.52 | Inst. Own | 83.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.60 | 200-d Avg | 2.17 | 1yr Est | 7.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -0.2 | -0.22 | -0.02 | -10.00% |
| 2024-08-06 | 2024-06 | -0.23 | N/A | N/A | N/A |
| 2024-08-06 | 2024-06 | -0.23 | -0.18 | 0.05 | 21.74% |
| 2024-05-02 | 2024-03 | -0.21 | N/A | N/A | N/A |
| 2024-05-02 | 2024-03 | -0.21 | -0.23 | -0.02 | -9.52% |
| 2024-03-06 | 2023-12 | -0.21 | -0.19 | 0.02 | 9.52% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-19 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-12-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-06 | Stephens & Co. | Upgrade | Overweight | Overweight |
| 2024-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-15 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-06-28 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
Profile
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-08-31 | CLACKSON TIMOTHY P | Director | 47.33K | Stock Gift |
| 2024-12-15 | FERRA JOSEPH J. JR. | Chief Executive Officer | 109.48K | Conversion of Exercise of derivative security |
| 2024-11-14 | FURLONG TAMMY CPA | Chief Financial Officer | 1.41K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Frazier Life Sciences Management, L.P. | 5.99M | 3.44M | 10.14% |
| 2024-09-29 | Tang Capital Management, LLC | 4.76M | 2.73M | 8.05% |
| 2024-09-29 | Goldman Sachs Group Inc | 3.99M | 2.29M | 6.75% |
| 2024-09-29 | Farallon Capital Management LLC | 3.53M | 2.02M | 5.97% |
| 2024-09-29 | Vanguard Group Inc | 3.07M | 1.76M | 5.20% |
| 2024-09-29 | BVF Inc. | 2.97M | 1.70M | 5.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.64M | 938.05K | 2.77% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.32M | 754.99K | 2.23% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 608.57K | 349.02K | 1.03% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 547.18K | 313.81K | 0.93% |
| 2024-08-30 | Vanguard U.S. Momentum Factor ETF | 431.95K | 247.73K | 0.73% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 294.43K | 168.85K | 0.50% |